CMS Natrecor NCD
Executive Summary
Medicare contractors may opt to cover J&J/Scios' Natrecor for some off-label uses despite a March 2 CMS national coverage decision against using nesiritide for chronic heart failure. The decision "does not change contractor discretion to cover other off-label uses of nesiritide" or affect coverage for the labeled indication of acutely decompensated heart failure, CMS said. The agency had expressed concern about the drug's potential for increased mortality rates and renal dysfunction. The NCD review found inconsistent data on use of Natrecor for chronic heart failure (1"The Pink Sheet" Dec. 12, 2005, p. 12)...
You may also be interested in...
Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.
Stage Set For Generics To Triumph With Skinny-Label Reversal
With the US solicitor general offering support for Teva over GSK in long-running litigation over skinny-label carve-outs of generic indications, the stage could be set for a major reversal at the Supreme Court that would favor the generics industry.